CA2673976A1 — Gel composition for treating mycosis
Assigned to Kaken Pharmaceutical Co Ltd · Expires 2008-07-10 · 18y expired
What this patent protects
It is intended to provide a gel composition for treating mycosis which is excellent in absorption and penetration of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)-butane-2-ol into a target site (skin and nails). Further, it is intended t…
USPTO Abstract
It is intended to provide a gel composition for treating mycosis which is excellent in absorption and penetration of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)-butane-2-ol into a target site (skin and nails). Further, it is intended to provide a gel composition for treating mycosis which is excellent in the stability of the medicament. It is a gel composition for treating mycosis containing (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)-butane-2-ol or an acid addition salt thereof, a lower alcohol, a polyhydric alcohol and a gel-forming polymer. Because the gel composition according to the invention has an excellent effect of penetration of KP-103 into a target site, and also exhibits an excellent effect of penetration thereof into nails, the medicament can be absorbed and penetrated directly and promptly into a target site constantly, therefore, it exhibits an excellent effect in the treatment of mycosis, particularly in the treatment of onychomycosis.
Drugs covered by this patent
- Jublia (EFINACONAZOLE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.